Dr. Benjamin Lilienfeld discusses Roche mass spectrometry solution launch
Roche Diagnostics leadership answers questions around cobas® mass spectrometry solution launch
Roche Diagnostics leadership answers questions around cobas® mass spectrometry solution launch
AI-powered solution to enhance diagnostic efficiency, streamline clinical trials, and improve patient outcomes across global pathology networks
Guest editorial by Dr. Benjamin Lilienfeld, Lifecycle Leader Serum Work Area Systems, Senior Vice President, Roche
This partnership is revolutionizing bladder cancer diagnostics with seamless access to non-invasive genomic testing and enhanced clinical efficiency
CLINICAL24 supporter, the Global Sepsis Alliance, advances global efforts to combat sepsis through leadership, advocacy, and community engagement
Join the CEO of MicrosensDx, Simon Walker, for a Q&A surrounding his collaboration with The Mayr Group at Imperial College London to develop a new sepsis test
Find out how CLINICAL24 supporter, UK Sepsis Trust is addressing workforce challenges and promoting early sepsis diagnosis in healthcare
Take the survey and submit a guest editorial
Clinical mass spectrometry testing offers sensitivity and specificity, providing clinicians with additional diagnostic insights
electronRx’s proprietary suite of digital solutions is dedicated to improving the lives of people with breathing disorders using smartphone technology to measure changes in cardiac and pulmonary functions to support them in making informed interventions
In this guest blog, Paul McCormick, Associate Practitioner, in Microbiology, discusses his daily routine, challenges, and technology solutions as part of the CLINICAL24 conversation
Guest editorial by Susan Dawson, Consultant, Speaker, Writer at Accomplish More Consulting Services (AMCS)
Expert roundtable forum discussion to explore the value of high-sensitivity immunoassays
Tropical Fever Panel a syndromic PCR test, targets the causes of tropical fever infections
A study suggests a new screening method that combines laser analysis with a type of AI is the first of its kind to identify patients in the earliest stage of breast cancer
The study was commissioned and funded by the National Institute for Health and Care Research (NIHR), and its leading partners were The University of Manchester, Northern Care Alliance NHS Foundation Trust and Warwick Medical School’s Clinical Trials Unit, who specialize in research in emergency and critical care
Find out how CLINICAL24 supporter, ADLM, advances clinical laboratory medicine by empowering laboratory professionals
T2 Biosystems announces plans to license its proprietary technology to accelerate the broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
Tell us which new products have had the biggest impact on your lab work for a chance to win one of five $100 Amazon.com Gift Cards
The PATHWAY HER2 (4B5) test helps identify patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA